Taltz® (Ixekizumab)

Para consultar la información para prescribir completa de Taltz® (Ixekizumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Ixekizumab: Impact on Itch in Psoriatic Arthritis Clinical Trials

The mean change from baseline in itch NRS in active psoriatic clinical trials is available.


Itch Data from Psoriatic Arthritis Clinical Trials

The safety and efficacy of ixekizumab is being evaluated in 3 phase 3, multicenter, randomized studies to assess safety and efficacy compared with placebo in patients with active PsA.1,2 Brief descriptions of the pivotal clinical trials for active PsA are provided in Appendix: Clinical Trials Brief Descriptions.

The change from baseline to week 12 in Itch NRS was a gated secondary endpoint in SPIRIT-P1. This outcome was not tested for statistical significance, as it did not meet the threshold for testing.3

The mean change in Itch NRS from baseline at week 12 and week 24 for patients who received ixekizumab Q4W and patients who received placebo during the 24-week double-blind placebo controlled treatment period of SPIRIT-P1 and SPIRIT-P2 is included below in Change From Baseline to Week 12 and Week 24 in Itch Numeric Rating Scale in SPIRIT-P1 and SPIRIT-P2 (Integrated), MMRM. Integrated data (SPIRIT-P1 and SPIRIT-P2) is shown.4

Change From Baseline to Week 12a and Week 24 in Itch Numeric Rating Scale in SPIRIT-P1 and SPIRIT-P2 (Integrated), MMRM4




12 Weeks

24 Weeks

12 Weeks

24 Weeks





LSM Change From Baseline in Itch NRS (SE)

-3.1 (0.19)

-3.1 (0.21)

-0.3 (0.20)

-0.7 (0.24)

Abbreviations: IXE Q4W = Ixekizumab 80 mg every 4 weeks following 160 mg starting dose; LEI = Leeds Enthesitis Index; LSM = least-squares mean; MMRM = mixed model for repeated measures; NRS = Numeric Rating Scale; PBO = Placebo; SE= standard error.

aItch NRS change from baseline at week 12 was a major secondary objective of SPIRIT-P1. Per multiple testing procedure, this is considered not significant, as the preceding endpoint (change in LEI) was not significant.


1Nash P, Kirkham B, Okada M, et al; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327. http://dx.doi.org/10.1016/S0140-6736(17)31429-0

2Mease PJ, Burmester G, Moriarty SR, et al. Safety of ixekizumab during 24 weeks of treatment in subjects with active psoriatic arthritis: Integrated safety analysis of two randomized, placebo controlled, phase 3 clinical trials. Poster presented at: 2017 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting; November 3-8, 2017; San Diego, CA.

3Mease PJ, van der Heijde D, Ritchlin CT, et al; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. http://dx.doi.org/10.1136/annrheumdis-2016-209709

4Data on file, Eli Lilly and Company and/or one of its subsidiaries.

5A long-term efficacy and safety study of ixekizumab (LY2439821) in participants with active psoriatic arthritis (SPIRIT P3). ClinicalTrials.gov identifier: NCT02584855. Updated November 15, 2019. Accessed September 25, 2020. https://www.clinicaltrials.gov/ct2/show/NCT02584855


bDMARD = biologic disease-modifying antirheumatic drug

NRS = numeric rating scale

PsA = psoriatic arthritis

Q4W = every 4 weeks

TNF = tumor necrosis factor

Appendix: Clinical Trials Brief Descriptions

  • SPIRIT-P1 (N=417) is a phase 3, 24-week double-blind, placebo-controlled trial with an active reference arm in patients with active PsA who are naïve to bDMARDs with an extension period of up to 3 years.3
  • SPIRIT-P2 (N=363) is a phase 3, 24-week double-blind, placebo-controlled trial in patients with active PsA and an inadequate response or intolerance to TNF inhibitor, with an extension period of up to 3 years.1
  • SPIRIT-P3 (N=570) consists of a 36-week open-label period followed by a randomized double-blind withdrawal period from week 36 to week 104. This trial is being conducted in patients naïve to bDMARDs.5

Fecha de la última revisión: 2020 M07 06

Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta